You are not paying close attention to these open positions!!! In fact my analysis says that the management is anticipating phase III failure. They are trying to shift to other therapeutic area of interest like oncology!!!
This will turn out to be a bigger than Madoff scandal!!!
Lot of people who are not familiar with drug development (not fundamental science) aspect, if a company is operating with inexperienced skill set (i.e. most of the people employed by this academic oriented company with strong fundamental science) the R&D cost will be higher because they will be doing things that are not necessary and not doing things that are very critical from the drug development/regulatory perspective.......Watch out, all these gene based companies (with very few exceptions) including BLUE, will crash in the near future!!!!